IBJNews

Lilly spent $1.9M lobbying feds in first quarter

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. spent $1.9 million lobbying the federal government in the first quarter, focusing on the health care overhaul and overseas pricing reform, among many other issues.

The maker of the antipsychotic Zyprexa and the antidepressant Cymbalta lobbied on the health care overhaul, the massive law that will eventually provide insurance coverage to millions of Americans. The law also imposes fees on the pharmaceutical industry.

Lilly also covered Medicare prescription drug rebate issues, hospital discounts, pricing reforms in Germany and Greece, and market access in Poland in the April-to-June period. The drugmaker, which is expanding its animal health business, also lobbied on food safety, veterinary medicine and antibiotic issues.

Besides Congress and the White House, Lilly also lobbied the Office of Management and Budget, the U.S. Trade Representative and the departments of State, Treasury, Agriculture, Commerce and Homeland Security.

Lobbyists are required to disclose activities that could influence members of the executive and legislative branches of government under a federal law enacted in 1995.

ADVERTISEMENT

  • Lilly diabetes issues
    Eli Lilly Zyprexa can cause diabetes.
    I took Zyprexa a powerful Lilly schizophrenic drug for 4 years it was prescribed to me off-label for post traumatic stress disorder was ineffective costly and gave me diabetes.
    -FIVE at FIVE-
    The Zyprexa antipsychotic drug,whose side effects can include weight gain and diabetes, was sold for “children in foster care, people who have trouble sleeping, elderly in nursing homes.”- *Five at Five* was the Zyprexa sales rep slogan, meaning *5mg dispensed at 5pm would keep patients quiet*.
    – Daniel Haszard

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT